Hepatosplenic cat-scratch fever with seropositivity for Bartonella quintana?

www.thelancet.com/infection Vol 8 November 2008 663 7 Ács N, Bánhidy F, Puhó E, Czeizel AE. Pregnancy complications and delivery outcomes of pregnant women with infl uenza. J Matern Fetal Neonatal Med 2006; 19: 135–40. 8 Irving WL, James DK, Stephenson T, et al. Infl uenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG 2000; 107: 1282–89. 9 France EK, Smith-Ray R, McClure D, et al. Impact of maternal infl uenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Arch Pediatr Adolesc Med 2006; 160: 1277–83. 10 Black SB, Shinefi eld HR, France EK, Fireman BH, Platt ST, Shay D. Eff ectiveness of infl uenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am J Perinatol 2004; 21: 333–39. 11 Zaman K, Roy E, Arifeen SE, et al. Maternal infl uenza immunization in mothers and infants. N Engl J Med 2008; published online Sept 17; DOI:10.1056/NEJMoa0708630. 12 Russell CA, Jones TC, Barr IG, et al. The global circulation of seasonal infl uenza A (H3N2) viruses. Science 2008; 320: 340–46. 13 Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of infl uenza vaccination during pregnancy. Am J Obstet Gynecol 2005; 192: 1098–106. 14 Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group Inc, 1977: 1–516. 15 Institute of Medicine. Immunization safety review: vaccines and autism. Washington, DC: The National Academy Press, 2004. 16 European Agency for the Evaluation of Medicinal Products. EMEA public statement on thiomersal in vaccines for human use—recent evidence supports safety of thiomersal-containing vaccines. London, 24 March. 2004. EMEA/CPMP/VEG/1194/04. http://www.emea.europa.eu/pdfs/ human/press/pus/119404en.pdf (accessed Sept 29, 2008). 17 Global Advisory Committee on Vaccine Safety. Statement on thiomersal. July, 2006. http://www.who.int/vaccine_safety/topics/thiomersal/ statement200308/en/index.html (accessed Sept 26, 2008). 18 US Food and Drug Administration. Thimerosal in vaccines. Updated June 3, 2008. http://www.fda.gov/cber/vaccine/thimerosal.htm (accessed Sept 26, 2008). 19 National Toxicology Program. Thimerosal [54-64-8]. Nomination to the National Toxicology Program. Review of the literature. April 2001. http:// ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/Thimerosal. pdf (accessed Sept 26, 2008). 20 Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23: 287–94.